Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Andrea Chiricozzi, MD
Department of Translational Medicine and Surgery
Rome, Italy

Andrea Chiricozzi is senior researcher at the Department of Translational Medicine and Surgery, Dermatology Unit, Catholic University of Rome, and dermatologist at the Fondazione Policlinico Universitario A. Gemelli I.R.C.C.S. Hospital. He qualified in Medicine at the University Campus Bio-Medico in Rome, Italy, in 2007. In 2012 he completed his residency training in Dermatology at the University of Rome Tor Vergata and received the Italian Board Certificate in Dermatology and Venereology. He worked as dermatologist in the Department of Dermatology, at the University of Rome Tor Vergata, till 2015. He was appointed as researcher at the Department of Translation and Clinical Medicine, Dermatology Unit, University of Pisa from 2016 to 2019. His scientific interests include skin immunology and inflammatory skin disorders, namely psoriasis, atopic dermatitis, and hidradenitis suppurativa. In particular, his scientific interests has been focused on the pathophysiology underlying the psoriatic plaque formation. His scientific activity on immune-mediated skin disorders was further developed at the Laboratory for Investigative Dermatology, headed by Prof. James G. Krueger at the Rockefeller University in NewYork, USA, as postdoctoral fellow and visiting dermatology. He has been investigator for multiple clinical trials testing biologic therapeutics, new oral and topical drugs for inflammatory skin disorders. He contributed as author to the most recent Italian Guidelines for the treatment of psoriasis and he has been involved in the Italian Registry for Biosimilars in Psoriasis and Psoriatic Arthritis (Psobiosimilars registry). He is author of more than 100 peer-reviewed articles and 4 book chapters. He was honored with the prestigious Leo-Pharma Research Silver Award in 2012.

Last Updated: Nov 19, 2019


PUBLICATIONS

1. Biomarkers of Disease Progression in People with Psoriasis: A Scoping Review. Ramessur R, Corbett M, Marshall D, Acencio ML, Barbosa IA, et al. Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21627. Epub ahead of print. PMID: 35482474.

2. Combined Single-Cell Transcriptome and Surface Epitope Profiling Identifies Potential Biomarkers of Psoriatic Arthritis and Facilitates Diagnosis via Machine Learning. Liu J, Kumar S, Hong J, Huang ZM, et al. Front Immunol. 2022 Mar 2;13:835760. doi: 10.3389/fimmu.2022.835760. PMID: 35309349; PMCID: PMC8924042. 

3. Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modelling. Soomro M, Stadler M, Dand N, et al. Arthritis Rheumatol. 2022 May 4. doi: 10.1002/art.42154. Epub ahead of print. PMID: 35507331.

Why these articles were chosen

In personalized care for patients, psoriasis biomarkers will be highly relevant. At present, various centers have investigated biomarkers and their clinical significance for psoriasis progression. We want to draw your attention to three recent publications, and we have asked an outstanding expert to provide his comments.

Commentary

Identifying biomarkers related to disease progression in psoriasis (PsO) represents a field of research that has been extensively explored. Clinical implications are dramatically relevant as the identification of biomarkers would help select those patients at risk of disease progression, defined as progression in disease severity and/or development of comorbidities, such as type II diabetes and arthritis (PsA).

Notwithstanding the efforts in identifying valuable candidates, no biomarkers are part of the routine practice as they are not supported by sufficient evidence. However, a scoping review1 analyzing 61 studies proposed a panel of 22 potential biomarkers of PsO progression, identified at the genomic, proteomic, and metabolomic levels. Most of them are involved in pathogenically relevant signaling pathways (i.e., IL-23/IL-17 pathway), antigen processing, and presentation (HLA-C*06:02, HLA-B*27, HLA-B*38, HLA-B*08), leucocyte recruitment (i.e., CXCL10) and activation (IL-13).

Eleven and fourteen candidates demonstrated potential biomarkers for disease severity and PsA development. A recent transcriptomic study attempted to identify additional potential biomarkers of PsA to facilitate early diagnosis via a machine-learning-based model.2 Overall, the study shed light on the differences between PsO and PsA in terms of circulating immune cell profile. Still, the machine-learning approach did not capture early or ephemeral biomarkers of disease progression in PsO patients who develop PsA.2 Other genetic risk factors predicting PsA development were investigated by Soomro M. et al.3 Their study proposed a novel susceptibility locus for PsA mapping on chromosome 22q11 and defined genes differentiating PsA from PsO (genes encoding members for NF- kB signaling and WNT signaling) through genome-wide meta-analyses. Nevertheless, the prediction model did not reveal any genomic risk factor for PsA, highlighting the modest performance of a risk model based on the currently available datasets.3 This finding confirmed the occurrence of multiple biases and methodological limitations in studies exploring the identification of biomarkers in psoriasis. Indeed, the ideal study is longitudinal in design, with a primary objective that should consist of the investigation of biomarkers related to disease progression. Information on key patient cohort characteristics (including participants’ ethnicity, age, psoriasis age-of-onset, and psoriasis subtypes) should be included. Confounding factors such as that ongoing therapies that could modify the course of disease and the accuracy in diagnosing comorbidities should be considered. These aspects were underlined by Ramessur R. et al., suggesting hints for designing and conducting future biomarker studies.1

Nowadays, a list of candidate biomarkers might be proposed, though they do not own sufficient evidence for clinical use without further validation. Thereby, identifying biomarkers predicting the risk of disease progression and/or development of comorbid conditions, in particular PsA, remains an important research question still unanswered.   


Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

  


IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis
 

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK